GlassScriptPhysician profile
Emmanuel R Lim
NPI 1275514234
$7,051.72
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,469 · 2020: $3,229 · 2021: $354.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,285.20 | 2019-2021 | |
| Viiv Healthcare Company | $1,199.63 | 2019-2021 | |
| Amgen INC. | $589.39 | 2019-2021 | |
| Emd Serono, INC. | $553.31 | 2019-2020 | |
| Novo Nordisk INC | $546.94 | 2019-2021 | |
| Janssen Biotech, INC. | $462.61 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $449.77 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $313.21 | 2019-2020 | |
| Pfizer INC. | $257.82 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.02 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.49 | 2019-2020 | |
| Allergan, INC. | $179.28 | 2019-2020 | |
| Mylan Specialty L.P. | $136.39 | 2019-2020 | |
| Lilly USA, LLC | $132.91 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $106.65 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $79.36 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $57.84 | 2019 | |
| Mannkind Corporation | $47.58 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.07 | 2019-2020 | |
| Horizon Therapeutics Plc | $38.24 | 2020 | |
| Antares Pharma, INC. | $32.28 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $23.39 | 2019 | |
| Abbvie INC. | $20.56 | 2021 | |
| Janssen Scientific Affairs, LLC | $18.67 | 2019 | |
| Amarin Pharma, INC. | $18.01 | 2019 | |
| Mylan Institutional INC. | $16.30 | 2019 | |
| Neurocrine Biosciences, INC. | $14.80 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.